Photo from wikipedia
For more than two decades, high‐dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B‐cell non‐Hodgkin's lymphoma (B‐NHL). However, the ideal timing… Click to show full abstract
For more than two decades, high‐dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B‐cell non‐Hodgkin's lymphoma (B‐NHL). However, the ideal timing and the collective patient benefits are still being debated.
Keywords:
patients aggressive;
dose chemotherapy;
high dose;
cell transplantation;
stem cell;
cell
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!